Oxford Biomedica plc, a gene and cell therapy group, has signed a new License and Supply Agreement (LSA) with an undisclosed U.S.-based late-stage cell and gene therapy company, granting the new partner a non-exclusive license to utilize Oxford Biomedica’s LentiVector platform for its application in their lead program, a cell-based therapy targeting a rare indication, putting into place a five-year clinical supply arrangement.
 
Under the terms of the LSA, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. The company will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of drug product sold that utilizes Oxford Biomedica’s LentiVector platform.
 
Dr. Roch Doliveux, chair and Interim CEO of Oxford Biomedica, commented, “This partnership further demonstrates Oxford Biomedica’s world leadership in the delivery of viral vectors for cell and gene therapies and the momentum we are building, with this being the fifth new or expanded customer partnership we have announced this year. We look forward to continuing to build upon our position as a partner of choice to deliver life-saving cell and gene therapies to patients.”